Animas Vibe With CGM System Launched In Canada

Espicom View: BMI 's Pharmaceuticals & Healthcare Canada Q1 2014 report estimates that there are currently 2mn diabetes sufferers living in Canada, with around half not having controlled treatment. Furthermore, BMI 's Burden of Disease Database estimates that 269,972 disability-adjusted life years were lost to diabetes in the country in 2013, and forecasts this to rise to 310,288 by 2018. This represents a clear market opportunity for Animas within the country.

Animas Canada ( LifeScan Canada [ Johnson & Johnson]) has launched the Animas Vibe insulin pump and continuous glucose monitoring (CGM) system in Canada, providing a new diabetes management solution for Canadians living with Type I diabetes. Expanding the global presence of Animas Vibe has been a top priority for Animas, and this launch marks its introduction to North America. Animas Vibe is also currently available in Europe, Australia and New Zealand.

Animas Vibe is an insulin pump with integrated CGM, featuring the Dexcom G4 sensor, the latest sensor technology from Dexcom. The launch of Animas Vibe marks the first time that this advanced CGM sensor technology from Dexcom is available as an integrated system with a pump to Canadians. CGM with Animas Vibe is indicated for adults aged 18 years and older only.

Animas Vibe is the first and only CGM-enabled insulin pump with a high-contrast colour screen, featuring colour-coded trend lines and arrows to indicate direction and rate of glucose change, revealing trends at a glance. CGM technology has been shown to provide improved glycaemic control in adult patients over 25 via lower HbA1c levels, less frequent hypoglycaemia and reduced glucose variability.

This article is tagged to:
Related sectors of this article: Medical Devices, Drug Delivery, Patient Aids, MIW
Geography: Canada, United States

Access all of our latest analysis, data and forecasts - request a trial